| Form | Liquid |
|---|
| Host Species | Humanized |
|---|
| Clonality | Monoclonal |
|---|
| Isotype | VH-VH'-VH |
|---|
| Purity | >95% as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G purified from cell culture supernatant. |
|---|
| Concentration | 0.52 mg/ml |
|---|
| Endotoxin Level | Please contact with the lab for this information. |
|---|
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Species Reactivity | Human |
|---|
| Target | TNF, Tumor necrosis factor ligand superfamily member 2, N-terminal fragment, ICD2, NTF, TNF-a, TNF-alpha, Tumor necrosis factor, TNFSF2, TNFA, Cachectin, ICD1, ALB, Albumin |
|---|
| Storage Buffer | 0.01M PBS, pH 7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. |
|---|
| Expression System | Mammalian Cells |
|---|
| Accession Number | P01375 & P02768 |
|---|
| Background | Ozoralizumab (ATN-103) is an anti-TNFα humanized antibody. Ozoralizumab is a humanized trivalent nanobody compound that consists of two anti-human TNFα nanobodies and an anti-human serum albumin (HSA) nanobody. Ozoralizumab can be used in research of arthritis.
|
|---|
| Alternative Names | Bispecific, ATN-103, 1167985-17-2 |
|---|
| Species | Human |
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|